Protara Therapeutics Completes Enrollment in Phase 2b Trial for IV Choline Chloride

Protara Therapeutics, Inc. (TARA) has finished enrolling 24 patients in the Phase 2b open-label dose confirmation portion of its THRIVE-3 clinical study. The trial evaluates intravenous Choline Chloride as a treatment for parenteral nutrition-dependent patients suffering from choline deficiency. Shares of the company traded down 5.34% to $2.48 following the update.

The completed enrollment marks a key milestone for the registrational Phase 2b/3 trial. IV Choline Chloride holds Orphan Drug and Fast Track designations, which provide regulatory benefits for treating this rare medical condition. If approved, the drug could become the first therapy on the market specifically designed for parenteral nutrition patients with choline deficiency. The study's primary endpoint measures changes in plasma choline levels to evaluate efficacy.

Looking ahead, the biopharmaceutical company expects to release interim results from the Phase 2b cohort during the fourth quarter of 2026. The forthcoming data will evaluate safety and pharmacokinetic profiles to guide dose selection for the subsequent Phase 3 stage of the program.